VRXA NASDAQ
Veraxa Biotech Holding AG
1W: -5.2%
1M: -14.5%
YTD: -79.8%
$1.98
-0.03 (-1.49%)
Weekly Expected Move ±26.2%
$1
$1
$2
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$280.0M
52W Range1.7-27.36
Volume306,650
Avg Volume418,160
Beta0.25
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOChristoph Antz
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-09
Websiteveraxa.com
Im Neuenheimer Feld 584
Heidelberg, ZH 69120
DE
Heidelberg, ZH 69120
DE
49 6221 3521330
About Veraxa Biotech Holding AG
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Latest News
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Recent Insider Trades
No insider trades found